Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats
- PMID: 8653704
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats
Abstract
The purpose of this study was to establish a nude rat orthotopic (organ-specific) human colorectal cancer model as an in vivo secondary screen for general evaluation of new anticancer agents against colorectal cancer and to evaluate practically the antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1), a new p.o. fluoropyrimidine, in comparison to 1 M tegafur-4 M uracil [(UFT) effective on colorectal tumor in clinical]. After implantation of KM12C, a human colorectal cancer cell line, into the subserosal layer of the colon as a single-cell suspension, extensive local tumor growth and invasion to both the mucosal and the serosal sides were observed in all rats. Metastatic foci were also formed in both lymph nodes and lungs following local tumor growth in all of them. Using this method, an equitoxic dose of S-1 (15 mg/kg/day) and UFT (30 mg/kg/day) was administered p.o. for 14 consecutive days from 7 days after tumor cell implantation. S-1 showed a higher tumor growth inhibition than UFT did [S-1, 57% (significantly different from the tumor weight of the untreated group at P < 0.05) and UFT, 18% (P > 0.05)]. When both drugs were administered to nude rats bearing KM12C injected into the cecal wall for 28 consecutive days at equitoxic doses, the mean survival in the S-1 group was 16 days longer than that in the untreated group (P < 0.01) but that in the UFT group was only 8 days longer (P > 0.05). After the administration of an equitoxic dose of both drugs, S-1 gave the higher levels than UFT in various pharmacokinetic parameters as follows: area under the curve 0-24 h of 5-fluorouracil in plasma (3.5-fold), area under the curve 0-24 h of 5-fluorouracil incorporated into RNA in the tumor (1.3-fold), and thymidylate synthase inhibition rate (percentage) in the tumor (about 20%). Collectively, these findings suggested that this orthotopic human colorectal tumor model in nude rats is useful to evaluate the clinical therapeutic efficacy of drugs or therapies for colorectal cancer, and that S-1 had a higher therapeutic effect on human colorectal tumor than UFT did.
Similar articles
-
Antitumor effect of S-1 on DMH induced colon cancer in rats.Anticancer Res. 1998 Mar-Apr;18(2A):1137-41. Anticancer Res. 1998. PMID: 9615778
-
[New oral anticancer drug, TS-1 (S-1)--from bench to clinic].Gan To Kagaku Ryoho. 2001 Jun;28(6):855-64. Gan To Kagaku Ryoho. 2001. PMID: 11432358 Review. Japanese.
-
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.Clin Cancer Res. 2004 Aug 1;10(15):4913-21. doi: 10.1158/1078-0432.CCR-04-0469. Clin Cancer Res. 2004. PMID: 15297391 Clinical Trial.
-
[Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].Gan To Kagaku Ryoho. 2001 May;28(5):655-60. Gan To Kagaku Ryoho. 2001. PMID: 11383214 Japanese.
-
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].Gan To Kagaku Ryoho. 1998 Feb;25(3):371-84. Gan To Kagaku Ryoho. 1998. PMID: 9492831 Review. Japanese.
Cited by
-
A phase 2 study of adjuvant carboplatin plus S-1 followed by maintenance S-1 therapy for patients with completely resected stage II/IIIA non-small cell lung cancer-Japanese Northern East Area Thoracic Surgery Study Group JNETS1302 study.J Thorac Dis. 2020 Jul;12(7):3591-3601. doi: 10.21037/jtd-20-715. J Thorac Dis. 2020. PMID: 32802438 Free PMC article.
-
Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study.J Natl Cancer Cent. 2023 May 19;3(2):115-120. doi: 10.1016/j.jncc.2023.05.003. eCollection 2023 Jun. J Natl Cancer Cent. 2023. PMID: 39035725 Free PMC article.
-
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.Br J Cancer. 2006 Jun 5;94(11):1575-9. doi: 10.1038/sj.bjc.6603168. Br J Cancer. 2006. PMID: 16721372 Free PMC article. Clinical Trial.
-
A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.Gastric Cancer. 2003;6 Suppl 1:34-9. doi: 10.1007/s10120-003-0230-y. Gastric Cancer. 2003. PMID: 12775018 Clinical Trial.
-
Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii.Int J Clin Oncol. 2023 May;28(5):613-624. doi: 10.1007/s10147-023-02326-w. Epub 2023 Mar 24. Int J Clin Oncol. 2023. PMID: 36961615
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources